Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Year: 2026
Type: article
Study design: Observational Study
Abstract: Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.
Source: Journal of Clinical Oncology
DOI: 10.1200/jco-26-01039
Authors: Saurabh Zanwar, Doris K. Hansen, Oren Pasvolsky, Carlyn Tan, Lauren C. Peres, Utkarsh Goel, Rakesh Popat, Aimaz Afrough, Sireesha Asoori, Masooma Rana, Mrugakshi Dave, Andrew Portuguese, Efstathios Kastritis, James A. Davis, Joaquin Martinez-Lopez, Douglas Sborov, Jana Mihalyova, Susan Bal, Murali Janakiram, Darren Pan, Leyla Shune, Christopher Ferreri, Noa Biran, Megan Herr, Ariel Grajales-Cruz, Jack Khouri, Andre De Menezes Silva Corraes, Omar Castaneda Puglianini, Emily C. Liang, Eli Zolotov, Tiffany Richards, Mahmoud Gaballa, Gliceida Galarza Fortuna, Kelley Julian, Kimberly Green, Aishwarya Sannareddy, Larry D. Anderson, Shahzad Raza, Danai Dima, Lekha Mikkilineni, Faiz Anwer, Shaji Kumar, Saad Usmani, Chiung-Yu Huang, Hira Mian, Surbhi Sidana, Krina Patel, Thomas Martin, Yi Lin, Luciano Costa, Melissa Alsina, Rachid Baz, Frederick L. Locke, Shebli Atrash, Cindy Varga, Peter Voorhees, Binod Dhakal, Hamza Hassan, Jeries Kort, Raffaela Cassano Cassano, Rahul Banerjee, Hossam M. Ali, Hitomi Hosoya, Christen Dillard, Lisa Lee, Amrita Krishnan
Institutions: Mayo Clinic, Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Cleveland Clinic, University College London Hospitals NHS Foundation Trust, The University of Texas Southwestern Medical Center, UCSF Helen Diller Family Comprehensive Cancer Center, Stanford Medicine, Stanford University, International Myeloma Foundation, Fred Hutch Cancer Center, National and Kapodistrian University of Athens, Medical University of South Carolina, Spanish National Cancer Research Centre, University of Utah, Huntsman Cancer Institute, University of Ostrava, University Hospital Ostrava, University of Alabama at Birmingham, City Of Hope National Medical Center, City of Hope, University of Kansas Medical Center, Levine Cancer Institute, Wake Forest University, Hackensack University Medical Center, Roswell Park Comprehensive Cancer Center, University of California, San Francisco, Juravinski Cancer Centre, McMaster University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7226018771
